Frazier Life Sciences Management, L.P. Macrogenics Inc Transaction History
Frazier Life Sciences Management, L.P.
- $1.7 Billion
- Q2 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Macrogenics Inc stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 3,010,727 shares of MGNX stock, worth $12.6 Million. This represents 0.75% of its overall portfolio holdings.
Number of Shares
3,010,727
Previous 2,471,704
21.81%
Holding current value
$12.6 Million
Previous $36.4 Million
64.83%
% of portfolio
0.75%
Previous 1.91%
Shares
6 transactions
Others Institutions Holding MGNX
# of Institutions
150Shares Held
60.4MCall Options Held
218KPut Options Held
259K-
Bellevue Group Ag Kuesnacht, V89.94MShares$41.7 Million0.71% of portfolio
-
Armistice Capital, LLC New York, NY6MShares$25.1 Million0.33% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$22.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.14MShares$17.3 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.31MShares$13.9 Million0.01% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $258M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...